Journal
MAYO CLINIC PROCEEDINGS
Volume 87, Issue 11, Pages 1106-1117Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.mayocp.2012.07.016
Keywords
-
Categories
Ask authors/readers for more resources
Clostridium difficile was first described as a cause of diarrhea in 1978 and is now among the leading 3 hospital-acquired infections in the United States, along with methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci. In the past 2 decades, there has been an increase in the incidence, severity, and recurrence rates of C difficile infection, all of which are associated with poor outcomes. In addition, several novel risk factors and newer treatment methods are emerging, including fidaxomicin therapy, treatment using monoclonal antibodies, and fecal microbiota transplantation, that have shown promise for the treatment of C difficile infection. This review focuses on the changing epidemiology, risk factors, and newer methods for treatment of C difficile infection. (C) 2012 Mayo Foundation for Medical Education and Research square Mayo Gin Proc. 2012:87(11):1106-1117
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available